SEER is an authoratitive source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
This tumor is very rare and may also be is reported as "cytokeratin-positive interstitial reticulum cell tumor". The tumor is histologically similar to follicular dendritic cell sarcoma or Interdigitating dendritic cell sarcoma (9757/3), but lacks the immunophenotypic profile of these tumor types. It derives from stroma-derived dendritic cells.
(This code is effective for cases diagnosed 2010 and later.) Fibroblastic reticular cell tumor is extremely rare. This neoplasm can manifest in lymph nodes, spleen, or soft tissue. The clinical outcome is variable with some patients dying of the disease. The tumor is similar to follicular dendritic cell sarcoma (9758/3) and Interdigitating dendritic cell sarcoma (9757/3) but lacks the immunophenotypic profile of these tumor types.
Definitive Diagnostic Methods
Variable reactivity for smooth muscle actin, desmin, cytokeratin (dendritic pattern) and CD68
Corresponding ICD-9 Codes
202.9 Other and unspecified malignant neoplasms
Corresponding ICD-10 Codes
C96.7 Other specified malignant neoplasms of lymphoid, hematopoietic
Corresponding ICD-10-CM Codes
(effective October 1, 2015 U.S. only)
C96.4 Sarcoma of dendritic cells (accessory cells)